Skip to main content

Table 1 Patient characteristics

From: Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study

Variables

Total (n = 201)

TP (n = 50)

TC (n = 151)

p

Age, years, n(%)

   

0.738

 < 65

143 (71.1)

37 (74)

106 (70.2)

 

 ≥ 65

58 (28.9)

13 (26)

45 (29.8)

 

Sex, n(%)

   

0.339

Male

175 (87.1)

46 (92)

129 (85.4)

 

Female

26 (12.9)

4 (8)

22 (14.6)

 

ECOG, n(%)

  

0.778

 

0

183 (91.0)

45 (90)

138 (91.4)

 

1

18 ( 9.0)

5 (10)

13 (8.6)

 

Smoking, n(%)

  

0.122

 

Yes

137 (68.2)

39 (78)

98 (64.9)

 

No

64 (31.8)

11 (22)

53 (35.1)

 

Drinking, n(%)

  

0.36

 

Yes

132 (65.7)

36 (72)

96 (63.6)

 

No

69 (34.3)

14 (28)

55 (36.4)

 

Tumor location, n (%)

  

0.284

 

Uper

30 (14.9)

4 (8)

26 (17.2)

 

Midle

71 (35.3)

19 (38)

52 (34.4)

 

Lower

100 (49.8)

27 (54)

73 (48.3)

 

Clinical T stage, n (%)

  

0.088

 

T2

12 ( 6.0)

5 (10)

7 (4.6)

 

T3

160 (79.6)

36 (72)

124 (82.1)

 

T4a

17 ( 8.5)

3 (6)

14 (9.3)

 

T4b

12 ( 6.0)

6 (12)

6 (4)

 

Clinical N stage, n (%)

  

0.749

 

N0

4 ( 2.0)

1 (2)

3 (2)

 

N1

73 (36.3)

21 (42)

52 (34.4)

 

N2

100 (49.8)

22 (44)

78 (51.7)

 

N3

24 (11.9)

6 (12)

18 (11.9)

 

Stage, n (%)

  

0.657

 

II

8 ( 4.0)

3 (6)

5 (3.3)

 

III

147 (73.1)

36 (72)

111 (73.5)

 

IVA

46 (22.9)

11 (22)

35 (23.2)

 
  1. ECOG: Eastern Cooperative Oncology Group performance